Year 2015 has brought mixed results for Ocata Therapeutics Inc (OTCMKTS:OCAT). Even though it got a good leader lately, but the objective of OCAT didn’t divert at all. It also announced that it would participate in the 17th Annual BIO CEO & Investor Conference to put forth its views in front of other market leaders.
Important Highlight Points of OCAT:
It is a leading name in the field of regenerative ophthalmology, and the Annual BIO CEO & Investor Conference was an ideal platform for the company to present its overview. The conference took place a few days ago and proved to be a grand success. Even though Ocata Therapeutics Inc (OTCMKTS:OCAT)’s representatives had a good time during the press conference, but immediately after that, they announced a news hardly a few would have expected.
OCAT made public that it would not be going forward with the previously announced public offering of 10.0 million shares. The reason for this withdrawal, as per Ocata Therapeutics Inc (OTCMKTS:OCAT)’s statement is nothing but the difficult market scenario, which is putting a lot of challenges in front of it. OCAT announced that it needs some more time to prepare itself before it could take things to greater heights.
Amidst these two important news, OCAT also announced the appointment of John Heffernan, a pharmaceutical industry leader, as its new Vice President of Manufacturing. The position has been created recently in order to strengthen the manufacturing unit of Ocata Therapeutics Inc (OTCMKTS:OCAT). Heffernan comes with an overall experience of more than 35 years and can add value to OCAT by helping it reach greater heights in the coming days.
Management of OCAT is delighted to welcome Heffernan and hopes that it will take the growth rate of Ocata Therapeutics Inc (OTCMKTS:OCAT) to a new level. OCAT is currently working on developing cure for Dry Age-related Macular Degeneration (Dry AMD) and Stargardt’s Macular Dystrophy (SMD). Heffernan will surely help it find a suitable treatment for the same in the near future.